Manufacturing Readiness Anthera is actively building manufacturing capacity with a senior VP of Manufacturing, signaling seriousness about scaling production for Sollpura and exploring external CDMO partnerships to support a potential commercial launch.

Diverse Late Stage Pipeline With Sollpura in phase three for exocrine pancreatic insufficiency due to cystic fibrosis and blisibimod in phase two for IgA nephropathy, the company presents multiple licensing or co development opportunities with specialty pharma players in GI and nephrology.

Financing and Partnerships A lean revenue base and modest funding position the company to pursue milestone based collaborations with larger biopharma or investors to fund late stage trials and commercialization efforts.

Differentiation Advantage Non pig derived liprotamase research offers potential differentiation in safety and supply chain resilience, which can strengthen conversations with distributors, payers, and regulatory partners.

Leadership Credibility Recent leadership moves and ongoing clinical development history provide credibility for joint development or licensing discussions, helping to accelerate deal negotiations with potential partners.